Find Clinical Trials

Inclusion Criteria: * HIV diagnosis * GAD-7 score of 5 or greater * PHQ-8 score of 5 or greater Exclusion Criteria: * Active psychosis * Suicidal ideation

Inclusion Criteria Participants meeting the following criteria will be included in the study: 1. Participant is assigned female or male at birth. 2. Participant is aged between 21 to 65 years, inclusive, at Screening. This is to reduce variability in brain function and connectivity in this small pilot study that may be related to age / developmental factors in persons under 21 and over 65. 3. Participant has a BMI of 18 to 30 kg/m2, inclusive, at Screening. 4. Participant has a diagnosis of PTSD (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition \[DSM-5\] established through a clinician interview that includes the Mini-International Neuropsychiatric Interview \[MINI\]) and the Clinician Administered PTSD Scale for DSM-5 (CAPS-5). 5. PTSD severity moderate to severe based on CAPS-5 score ≥25, and with moderate depression MADRS ≥20. 6. Participants capable of producing sperm must use a condom during the trial and for 3 months after their dose of trial medication, if their partner is a person of childbearing potential. In addition, their partner of childbearing potential must also use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) from dosing until 3 months following dosing. Condoms alone and abstinence are not considered highly effective methods of contraception. 7. Participants of childbearing potential must agree to use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) in combination with use of a condom by a partner who is capable of producing sperm, during the trial and for 3 months after dosing. Condoms alone and abstinence are not considered highly effective methods of contraception. Such participants must have a negative pregnancy test at Screening and Day 1. 8. Participants of non-childbearing potential who are or were capable of producing eggs (ova) must be postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy or bilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for at least 12 months, and a serum follicle stimulating hormone (FSH) level in the menopausal range, unless the participant is taking hormone replacement therapy or is using hormonal contraception. 9. Provision of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. If appropriate, describe why certain populations may be excluded (e.g., non-English speaking individuals for studies involving informed consent). Exclusion Criteria Participants with the following will be excluded from study participation: 1. Cardiovascular disease, including coronary artery disease (CAD) and congestive heart failure (CHF). This is an FDA requirement. 2. Current or previously diagnosis of schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder or brief psychotic disorder; current or previous history of bipolar disorder, or current personality disorder (as determined by MINI at Screening). This is an FDA requirement. 3. Clinically significant risk of suicidality, as determined through a comprehensive psychiatric interview that incorporates the Columbia Suicide Severity Rating Scale (CSSRS); a score of 4 or higher on the suicidal ideation subscale of C-SSRS (past 6 months) or any suicidal behaviour (lifetime), would be exclusionary. 4. History of substance use disorder within the 12 months, as assessed by a structured clinical interview (Mini International Neuropsychiatric Interview \[MINI\], Version 7.0.2) or determined by self-report, or intake of \>21 units of alcohol weekly, and the inability to refrain from alcohol use from 48 hours before Screening and each scheduled visit until discharge from the study site. One unit is equivalent to a 285 mL glass of full-strength beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine. 5. Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, other non-SSRI or non-SNRI antidepressants (e.g. bupropion, mirtazapine, etc), an antipsychotic or a mood stabilizer. 6. Exposure to psilocybin, or any other psychedelics, such as ayahuasca, mescaline, LSD or peyote more than 10 times in the last 10 years, or any psychedelic use within 6 months prior to Screening. 7. Use of psychotropic medicine/supplement (or medicine/supplement that would interact with psilocybin) including buspirone and venlafaxine, during the 28 days before dosing. Participants may take a stable chronic dose of other SSRI antidepressant medication(s) and/or sedatives/hypnotics. The Investigator and study team may review medication on a case-by-case basis to determine if its use would compromise participant safety or interfere with study procedures or data interpretation. 8. Family history of schizophrenia or schizoaffective disorder (first degree relatives), or bipolar disorder type 1 (first degree relatives). 9. Clinically relevant history of abnormal physical health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including \[but not limited to\], neurological, endocrine, cardiovascular, respiratory, gastrointestinal (including dyspepsia or gastroesophageal reflux disease), hepatic, or renal disorder). 10. Participant has a presence or relevant history of any of the following medical conditions: organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions). 11. Diagnosis of hypertension or arrhythmia. 12. Clinically relevant abnormal heart rate (resting supine heart rate \>100 bpm) or blood pressure (resting supine systolic blood pressure (SBP) above 140 mmHg or diastolic blood pressure (DBP) above 90 mmHg) at screening. Screening supine SBP, DBP and heart rate for evaluation will be the average of 3 readings obtained after at least 5 minutes rest. Participants with abnormal vital signs which are out of range and deemed clinically significant by the Investigator at Day 1, following triplicate readings. 13. Presence of clinically significant ECG abnormalities at the Screening visit, as defined by medical judgement. 14. QT interval corrected for heart rate using Fridericia's formula (QTcF) \>450 msec at Screening, following triplicate ECG readings. 15. Hypothyroidism and/or current abnormal thyroid function tests. In case of uncertain or questionable screening thyroid function test results, the TSH test may be repeated once during screening. The TSH test must be reviewed to ensure that it is within normal limits before randomizing a participant into the study. 16. Clinically relevant abnormal laboratory results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), 12-lead ECG and vital signs, or physical findings at Screening. In case of uncertain or questionable results, tests performed during Screening may be repeated once to confirm eligibility or judged to be clinically irrelevant. 17. Other eligibility considerations (i.e., participant personal circumstances, behavior, and/or any current problem that might interfere with participation or that is incompatible with establishment of rapport or safe exposure to psilocin), as judged by the Investigator. 18. History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion (ADME) of the study drug. 19. Any other concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study as outlined in this Protocol, or that would, in the opinion of the Investigator, pose an unacceptable risk to the pa

Inclusion Criteria: * Patients with breast cancer diagnosed with stage I-III; * Planned to receive 4 cycles of taxane chemotherapy and have not taken neurostable drugs within three months; * 18 years old≤ age≤ 75 years old, female; * Subjects voluntarily participate in this trial and sign the informed consent form. Exclusion Criteria: * Patients who have had acupuncture treatment in the past; * After examination by a doctor, there is a local infection at or near the acupuncture site, which is not suitable for acupuncture. * Platelets\< 50,000/μL; * Patients with CIPN≥1 grade 1 (NCI-CTCAE); * Peripheral neuropathy or other neuropathic pain caused by diabetes mellitus or other factors related to HIV infection.

Inclusion Criteria: * Age 18 years or older * Has moderate or severe baseline anxiety or depression, as defined by GAD-7 ≥ 10 or PHQ-9 ≥ 10, respectively * Based in the US * Fluent in the English language * Has an email account to receive and complete online surveys * Has access to a smartphone, tablet or computer * Able to understand and provide informed consent Exclusion Criteria: * Pregnant or plan on becoming pregnant in the next 6 months * Has no or mild baseline anxiety or depression, as defined by GAD-7 \< 10 and PHQ-9 \< 10, respectively

Inclusion Criteria: * Age 18 or older * Patients with a viable pregnancy \<23 weeks of gestation * Chronic hypertension is defined as: 1) Currently receiving treatment for hypertensive disorders OR 2) Newly diagnosed or untreated chronic hypertension is defined as systolic blood pressure \>=140 mm Hg or diastolic blood pressure \>=90 mm Hg prior to 20 weeks of gestation * Viable pregnancy \<23 weeks of gestation * Ability to follow directions * Ability to consent * Speak English or Spanish Exclusion Criteria: * Known secondary cause of hypertension * Known major fetal anomaly * Known fetal demise * Suspected fetal growth restriction * Membrane rupture * Planned termination * Plan to deliver outside of the RWJ Barnabas Health system * Known sensitivity to labetalol or nifedipine * Unlikely to follow up, in the opinion of the study staff. * Any medical condition that the providers feel is a contraindication to the REACH algorithm. * Unwillingness to take blood pressure at home

Main Inclusion Criteria: * Signed informed consent and the subject's ability to comply with the requirements of the Clinical Study Protocol. * Age ≥18 years and \<75 years at the time of signing the informed consent form. * Histologically verified diagnosis (there are documented results of relevant studies) of TNBC: ER 0-2 points, PR 0-2 points or ER \<1%, PR \<1% (ASCO/CAP); HER2 (≤1+) or HER2 (2+) in the absence of amplification of the Her-2-neu gene by ISH. * TNBC is progressive or relapsing on or after systemic therapy. * The subject received at least 1 line of systemic therapy for locally advanced unresectable or metastatic TNBC, or she experienced a relapse / progressive disease during or within 6 months after completion of post-operative (adjuvant) chemotherapy. * Confirmed AXL expression in tumor cells according to immunohistochemistry. * Availability of fresh (obtained as part of screening or before its start, but after disease progression or relapse on the last line of therapy) and archival (obtained before disease progression or relapse on the last line of therapy, if available) tumor material samples suitable for immunohistochemical examination to determine AXL expression. * Presence of at least 1 measurable tumor lesion according to RECIST 1.1. criteria for CIR. * ECOG score 0-1. * Life expectancy ≥ 4 months from the date of signing of the informed consent form in the opinion of the Investigator. Main Exclusion Criteria: * Indications for radical therapy or radiotherapy (excluding minor surgery or radiation therapy for palliative purposes). * Active CNS metastases and/or carcinomatous meningitis. Subjects with brain metastases may participate in the study provided that the metastases have been adequately treated with surgery or radiotherapy, and if they have been clinically stable for at least 4 weeks prior to randomization (i.e. no neurological symptoms, no need for corticosteroids, and no lesions \>1.5 cm) and no evidence of new or increasing CNS metastases. Patients with newly diagnosed CNS metastases during screening may not be included in the study.

Inclusion Criteria: 1. Has newly diagnosed Stage II or III histologically confirmed invasive breast carcinoma. 2. Has histologically confirmed HER2-positive breast cancer 3. Has a known hormone receptor (HR) status of the primary tumor 4. Participants with multifocal or multicentric disease are eligible if the largest tumor (which must be larger than or equal to 2 cm in diameter) is HER2-positive, and the treating physician has determined the participant should be treated as HER2-positive. 5. Agrees to undergo a mastectomy or breast conserving surgery (BCS) after neoadjuvant therapy. 6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Adequate organ function 8. Has an LVEF ≥ 50% as determined by either ECHO or MUGA obtained within 6 weeks prior to randomization. 9. Adequate contraceptive precautions 10. Participants with known HIV are eligible unless: 1. CD4+ T Cell count is less than or equal to 350 microliters (uL) 2. Detectable viral load, or 3. Receiving protease inhibitors or cobicistat Exclusion Criteria: 1. Has Stage IV (metastatic) breast cancer. 2. Has bilateral breast cancer. 3. Has a history of any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator, could affect the participant's involvement in the study. 4. Has uncontrolled hypertension 5. Has significant symptoms from peripheral neuropathy 6. Has an active uncontrolled infection 7. Has a history of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in the drug formulation of zanidatamab or other study interventions. 8. Known active hepatitis B or C infection. 9. Has another malignancy diagnosed within the last 5 years. Exceptions include previously treated non melanomatous skin cancers, carcinoma in-situ, and melanoma in-situ. Participants with prior ipsilateral ductal carcinoma in situ (DCIS) or invasive breast cancer are not eligible. 10. Was treated with surgery, chemotherapy, anti-HER2 therapy, radiation therapy, endocrine therapy, or experimental therapy for invasive breast cancer 11. Is planning to receive concurrent therapy with any other investigational agent or anti-cancer therapy not specified in the protocol 12. Receipt of a live vaccine within 4 weeks prior to enrollment 13. Has a known hypersensitivity to any components of the study interventions, including chemotherapy

Inclusion Criteria: * Female participants aged 18-80 years * Unilateral upper extremity lymphedema secondary to breast cancer surgery * Diagnosed with lymphedema at International Society of Lymphology (ISL) Stage 0, I, II, or III * Willing and able to provide informed consent Exclusion Criteria: * Bilateral upper extremity lymphedema * Cognitive or mental disorders that interfere with cooperation * Neurological diseases * Active infection * Scleroderma or other skin disorders affecting elasticity * Significant cardiac conditions that may interfere with assessment

Inclusion Criteria: * German language skills * Reading and writing skills * Internet access * Employee status * Consent to participate in the study Exclusion Criteria: * Illiteracy * Massively limited cognitive abilities i.e. linguistic components of the digital offerings must be able to be used, and questionnaires completed, or interviews participated in)

Inclusion Criteria: I. Currently hospitalized due to pulmonary infection (ICD-10 codes: J00.x to J22.x). II. Diagnosed with type 2 diabetes mellitus (ICD-10 codes: E10.x or E11.x). III. Aged between 18 and 90 years. IV. Able to communicate verbally or non-verbally and understand Mandarin or Taiwanese. V. Willing to participate in the study and consent to group assignment. Exclusion Criteria: I. Modified Rankin Scale (mRS) score ≥ 5, indicating severe functional impairment. II. Diagnosed with dementia (unable to comprehend or follow intervention instructions). III. Presence of acute psychiatric symptoms that impair communication. IV. Individuals with high litigation risk. V. Diagnosed with chronic obstructive pulmonary disease (COPD) or any other chronic respiratory diseases. VI. Diagnosed with glucose-6-phosphate dehydrogenase (G6PD) deficiency (ICD-10 codes: D55.x, D74-75.x).

Inclusion Criteria: Adults aged 65 years and older Clinically diagnosed with asthma (physician-confirmed) Stable asthma (no hospitalizations for asthma in the past 30 days) Able to understand and provide informed consent Willing and able to participate in a 12-week nursing intervention program Has access to a telephone or internet-enabled device for coaching sessions and monitoring Resides in an area prone to climate-related environmental stressors (e.g., urban heat, poor air quality) Exclusion Criteria: Diagnosis of chronic obstructive pulmonary disease (COPD) or other significant pulmonary conditions (e.g., interstitial lung disease) Severe cognitive impairment (e.g., diagnosed dementia) that would interfere with participation Current participation in another asthma-related interventional study Residing in long-term care facilities where independent asthma self-management is not feasible Any unstable medical condition that could confound outcomes or pose safety risks, as determined by the study physician

Subject Characteristics Inclusion Criteria: 1. adults (18-65 years old) 2. Ability to provide informed consent 3. English language proficiency 4. PHQ-9 score \> 10, indicating at least moderate depressive symptoms 21 5. Must have filled out the waiver for the community-based partners prior to enrolling in the study\* 6. Individuals of childbearing potential must use an acceptable form of birth control 7. (if applicable) willingness to keep psychiatric medications and psychotherapy stable throughout the course of the study 8. Must be able to access mindfulness app on a device (i.e., smartphone, iPad, etc.) 9. Can travel to Breathe in Harvard Square and at least one Restore location (i.e., Hingham, Somerville, Dedham, Newton, Lynnfield) Exclusion Criteria: 1. Pregnant or planning to become pregnant 2. Breast feeding 3. Active suicidal thinking (i.e., PHQ-9 item 9 ≥1 and a positive response to C-SSRS screener items 3, 4, 5, or 6) 4. Active eating disorders or substance use disorders within the past 12 months, as per the MINI 5. Primary OCD or PTSD, as per the MINI 6. History of bipolar disorder, psychotic disorders, as per the MINI 7. ≥25% drop in PHQ-9 score from screen to baseline 8. Under the influence or withdrawal of drugs or alcohol 9. Positive urine toxicology screen due to illicit drug use or other exclusionary medications. (Potential false positives will be addressed on a case-by-case basis at the discretion of the PI or designee) 10. have had a bone fracture or joint surgery in the past 6 months 11. not able to walk freely or without difficulty 12. any serious, unstable medical condition as determined by the revised Physical Activity Readiness Questionnaire (PAR-Q+) and do not have approval from their treating physician (we will check in with treating physician in the event that participants endorse any item on the PAR-Q+) 13. participants must have a healthcare provider who they could contact if they needed medical care, such as a primary care doctor, a counselor, a psychiatrist, a nurse practitioner, or a clinic that you go to. 14. Significant exposure to heated yoga classes in the past 3 months (i.e., more than 6 classes) 15. Significant exposure to sauna sessions in the past 3 months (i.e., more than 6 sessions) 16. Significant exposure to mindfulness app in the past 3 months (i.e., more than 6 uses of the app) 17. are on medications that make dehydration more likely (e.g., lithium, antipsychotics, insulin-dependent) diuretics, barbiturates, b-blockers, anticholinergics, current ETOH acute intoxication, reduced ability to sweat, hemophilia, pacemaker (magnets used to assemble saunas can interrupt the pacer) 18. antidepressant or psychiatric medications that are initiated less than 8 weeks or a dose change less than 4 weeks prior to screening visit 19. psychotherapy that has been initiated within the past 3 months 20. psychiatric hospitalization within the past year 21. diagnosed with any neurological disorders that would impact participation or make participation unsafe 22. are currently in active ketamine, Electroconvulsive therapy, or Transcranial Magnetic Stimulation treatments 23. are unable to follow the study procedures (e.g., not able to travel to the heated yoga or sauna studios) 24. A subject who in the opinion of the Principal Investigator would not be able to safely complete the study or would jeopardize study integrity

Inclusion Criteria: * Aged ≥18-years * Verbal and written proficiency in English * United Kingdom resident (General Practitioner registered) * Basic computer literacy * Email address to register with Orbi * Have a long-term physical health condition * Are experiencing distress related to their long-term physical condition Exclusion Criteria: * Evidence of substance dependency, cognitive impairment, severe mental health conditions identified by adhering to usual care Improving Access to Psychological Therapies (IAPT) screening practices that are employed at assessment and triage * Those with evidence of severe depression and/ or anxiety scoring over 6 on the Patient Health Questionnaire-4 (PHQ-4) eligibility questionnaire or scoring 1 or above on the eligibility Patient Health Questionnaire-9 (PHQ-9) suicide risk question * Receiving active psychological treatment from psychologist/counsellor/therapist or online psychological intervention

Inclusion Criteria: * Histologically confirmed diagnosis of non-metastatic breast cancer: stages cT1-T4, cN0-N3, M0, and candidates for neoadjuvant chemotherapy (NAC). * Age ≥ 18 years. * Signed informed consent. Exclusion Criteria: * Contraindication or physical inability to perform moderate-to-high intensity physical exercise. * Pregnant or breastfeeding patients. * Presence of other active synchronous neoplasms. * Metastatic breast cancer (stage IV). * Patients already engaging in regular physical exercise: more than 150 minutes of moderate or intense aerobic exercise per week. * Male breast cancer patients. * Personal history of a previous malignancy treated with chemotherapy. * Severe or poorly controlled psychiatric illness (including uncontrolled active substance abuse).

Inclusion Criteria: * Patients must be at least ≥ 18 years of age * Histologically confirmed hormone receptor positive metastatic breast cancer: Tumors that are positive for estrogen receptor (ER) and/or progesterone receptor (PR) * HER2-negative or HER2-low will be included and defined as: * 0-1+ HER2 expression by immunohistochemistry (IHC) OR * Fluorescence in situ hybridization (FISH) negative OR * HER2 2+ and FISH negative * HER2 low per standard of care in breast cancer * Patients should be receiving the following therapies to be eligible for the study: * Cohort 1: First or second line of endocrine therapy in the metastatic setting, in combination with a CDK4/6 inhibitor. Patients must have completed at least 2 cycles of CDK4/6 inhibitor. Patients who have stopped endocrine therapy for intolerance but remain on abemaciclib monotherapy will be considered for enrollment at the PI's discretion * Cohort 2: Progressed on endocrine-based therapies and after completion of at least 1 cycle of capecitabine * Subjects with Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1 * Willing to undergo up to two serial biopsies while on study * Have at least 1 site of disease confirmed by the treating oncologist that could be biopsied during treatment * White blood cell (WBC) ≥ 2000/mm\^3 (within 28 days of receiving the study vaccine) * Lymphocyte count ≥ 500/mm\^3 (within 28 days of receiving the study vaccine) * Absolute neutrophil count (ANC) ≥ 800/µL (within 28 days of receiving the study vaccine) * Platelets ≥ 75,000/µL (within 28 days of receiving the study vaccine) * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except patients with Gilbert's syndrome in whom total bilirubin must be ≤ 3.0 mg/dL (within 28 days of receiving the study vaccine) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x institutional upper limit of normal (ULN) (within 28 days of receiving the study vaccine) * Creatinine ≤ 2.0 mg/dL or creatinine clearance \> 30 mL/min (within 28 days of receiving the study vaccine) * Patients of child-bearing potential must agree to use dual methods of contraception and have a negative urine pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or postmenopausal. Effective methods of contraception must be used throughout the study and until the end of treatment on study * Must have recovered from major infections and/or surgical procedures; and in the opinion of the investigator, not have any significant active concurrent medical illnesses or condition precluding protocol treatment Exclusion Criteria: * Patients with any of the following cardiac conditions: * Symptomatic restrictive cardiomyopathy * Dilated cardiomyopathy * Unstable angina within 4 months prior to enrollment * New York Heart Association functional class III-IV heart failure on active treatment * Symptomatic pericardial effusion * Uncontrolled hypertension * Uncontrolled cardiac arrhythmias * Patients with any autoimmune disease/comorbidity that require chronic steroids or immunosuppressants * A non-breast malignancy requiring radiation or systemic therapy within last 5 years * Known hypersensitivity reaction to the granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant; any known contra-indication to GM-CSF * Pregnant or breast feeding * Known history of human immunodeficiency virus (HIV) infection, hepatitis B (e.g., hepatitis B virus surface antigen \[HBsAg\] reactive), or hepatitis C (e.g., hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected) * Major surgery within the 4 weeks prior to initiation of study vaccine * Current use of immunosuppressive agents or systemic corticosteroids. Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are allowed. Patients who have received systemic corticosteroids ≤ 30 days prior to starting study drug will be excluded * Patient is currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug * NOTE: Biomarker or tissue collection or any other non-interventional clinical trial enrollment is allowed * Must be 14 days between a non-study vaccine and any STEMVAC vaccination * NOTE: The minimum of 14 days does not apply to the tetanus and diphtheria (Td) vaccine * Any condition that may interfere with the patient's participation in the study per treating oncologist

Inclusion Criteria: * Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening. * Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening: Metformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist. * Need of intensification with basal insulin, as indicated at the discretion of the investigator. * Recorded HbA1c value ≥7% within the last 90 days prior to randomization. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Previous participation in this study. Participation is defined as signed informed consent. * Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method. * Participation (i.e., received any study intervention) in any interventional clinical study within 90 days before screening. * Any disorder which in the investigator's opinion might jeopardize participant's safety.

Inclusion Criteria: 1. Adults (≥ 18 years) 2. Having a diagnosis of a. Breast Cancer, b. Colorectal Cancer, or c. Head and Neck Cancer. 3. Having concluded the planned chemotherapy courses and related hospital admissions 4. Having no more than 5 years since the initial diagnosis. Exclusion Criteria: 1. Being in active psychological or psychiatric treatment 2. Having an unmanaged mental health difficulty 3. Having a severe cognitive impairment 4. Being unable to give informed consent 5. Being unable to speak or read Greek 6. Having one or more relapses 7. Diagnosed with another type of cancer within 5 years prior to recruitment. 8. Having less than one-year life expectancy

Inclusion Criteria: * cT1-2N1M0 breast cancer\* * FNA or core biopsy confirmed axillary nodal metastases * ≤2 abnormal nodes on imaging * Undergo a dual tracer or single tracer sentinel node biopsy along with removal of the marked node (Targeted Sentinel Node Biopsy, TSNB) * 1 or 2 macrometastases identified in the removed nodes, with at least three nodes removed * If the sentinel node(s) cannot be localised on SNB: axillary node sampling should be performed, the patient will be eligible if 1 or 2 macrometastases are identified in the removed nodes, with at least three nodes removed. * If the node is not marked or the marked node is not removed, the patient will be eligible if 1 or 2 macrometastases are identified in the removed nodes, with at least three nodes removed. * patients with T3 tumours on post-operative histology will remain eligible. Exclusion Criteria: * Neoadjuvant chemotherapy * Previous ipsilateral axillary lymph node dissection * cT3-4 breast cancer * ≥3 abnormal nodes on imaging

Inclusion Criteria: * dense breasts (BI-RADS C or D) on screening DBT Exclusion Criteria: * pregnancy

Key Inclusion Criteria: * 18 years of age or older * Diagnosed with one of the following at least 3 months prior to screening: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder * Diagnosed with at least mild neuroleptic-induced TD for at least 3 months prior to screening Key Exclusion Criteria: * Have comorbid Parkinsonism or abnormal involuntary movement(s) that is more prominent than TD * Diagnosis of moderate or severe substance use disorder in the last 6 months * History of long QT syndrome, cardiac arrythmia, or severe hepatic impairment